Vous n'êtes pas connecté
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Saisei Ventures, a leading investment firm focused on advancing Japanese biotechnology and therapeutic innovations, today announced that Mr. James Feliciano has been appointed venture partner. With more than 20 years of experience as a pharmaceutical executive in Japan, Mr. Feliciano is a world-class leader in advancing innovative therapies and guiding global teams to success. Most recently, he founded 3C Advisors GK, a Tokyo-based strategic advisory firm partnering with organizations to navigate the complexities of the Japanese market...
Eduardo Martinez Diaz, Cuban deputy prime minister, described the opening of the Biopharmaceutical Research Institute, part of the Cuban-Chinese joint...
A multinational pharmaceutical and biotechnology company here has introduced a medical breakthrough that could provide therapeutic options to patients...
Ocugen, Inc., a pioneering biotechnology leader in gene therapies for blindness diseases, executed a licensing agreement with Kwangdong...
September 17, 2025 08:11 ET | Source: RealSimple RealSimple Denver, CO, Sept. 17, 2025 (GLOBE NEWSWIRE) — Convergent Wealth Advisors...
HONG KONG SAR – Media OutReach Newswire – 11 September 2025 – BeOne Medicines (BeOne)(NASDAQ: ONC; HKEX: 06160; SSE: 688235), was honored today...
HONG KONG SAR – Media OutReach Newswire – 11 September 2025 – BeOne Medicines (BeOne)(NASDAQ: ONC; HKEX: 06160; SSE: 688235), was honored today...
HONG KONG SAR – Media OutReach Newswire – 11 September 2025 – BeOne Medicines (BeOne)(NASDAQ: ONC; HKEX: 06160; SSE: 688235), was honored today...
Divisional Commander for the St James Police, Senior Superintendent Eron Samuels, is encouraging residents of the parish to continue partnering with...